Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q1 2026 vs. Q4 2025
How the institutions holding Jasper Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 55 | 1 | 58 | +4 |
| Shares | 19.2M | 1.33M | 15.8M | −2.08M (−11.6%) |
| Value | $35.2M | $2.43M | $13.9M | −$18.9M (−57.7%) |
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Kingdon Capital Management, L.L.C. | 1,352,106 | $1.18M | 0.20% |
| Vanguard Capital Management LLC | 1,172,597 | $1.03M | 0.00% |
| Vanguard Fiduciary Trust Co | 149,943 | $131.3K | 0.00% |
| Verdad Advisers, LP | 73,967 | $64.8K | 0.07% |
| Marshall Wace, LLP | 45,656 | $40.2K | 0.00% |
| Nine Masts Capital Ltd | 44,165 | $38.7K | 0.01% |
| XTX Topco Ltd | 39,431 | $34.5K | 0.00% |
| Diker Management LLC | 35,000 | $30.7K | 0.03% |
| Simplex Trading, LLC | 29,273 | $25.6K | 0.00% |
| Rehmann Capital Advisory Group | 15,300 | $13.4K | 0.00% |
| LPL Financial LLC | 12,250 | $10.7K | 0.00% |
| Vanguard Global Advisers, LLC | 3,972 | $3.48K | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $1 | 0.00% |
Sold out (9)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Goldman Sachs Group Inc | 1,746,492 | $3.20M |
| Woodline Partners LP | 1,040,704 | $1.90M |
| T. Rowe Price Investment Management, Inc. | 964,754 | $1.77M |
| Sphera Funds Management Ltd. | 485,401 | $888.3K |
| Quadrature Capital Ltd | 67,267 | $123.1K |
| FMR LLC | 11,949 | $21.9K |
| Citigroup Inc | 642 | $1.18K |
| Barclays PLC | 1 | $2 |
| Avion Wealth | 214 | $0 |
Not filed for Q1 2026 yet (1)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 1,326,512 | $2.43M |